Search

Displaying results 2171 - 2180 of 10000 in total
  1. Drug

    Lamivudine

    go.drugbank.com/drugs/DB00709
    ApprovedInvestigational

    A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring.

    Mixtures: N/A, N/A
  2. Drug

    Nialamide

    go.drugbank.com/drugs/DB04820
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.

  3. Drug

    Mitapivat

    go.drugbank.com/drugs/DB16236
    ApprovedInvestigational

    Mitapivat is a novel, first-in-class pyruvate kinase activator. It works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells. … [A245478] On February 17, 2022, the FDA approved mitapivat as the first disease-modifying treatment for hemolytic anemia in adults with pyruvate kinase (PK) deficiency, a rare, inherited disorder leading

  4. Drug

    Calcium ascorbate

    go.drugbank.com/drugs/DB14483
    ApprovedNutraceutical

    Mixtures: Supplements De Vitamines Et Mineraux, Am CapsCategories: Compounds used in a research, industrial, or household setting
  5. Drug

    Trabedersen

    go.drugbank.com/drugs/DB05697
    Investigational

    Synonyms: DNA, D(P-THIO)(C-G-G-C-A-T-G-T-C-T-A-T-T-T-T-G-T-A)
  6. Drug

    Ethoxzolamide

    go.drugbank.com/drugs/DB00311
    ApprovedWithdrawn

    Ethoxzolamide is a sulfonamide used as diuretic and in glaucoma. It inhibits carbonic anhydrase activity in proximal renal tubules to decrease reabsorption of water, sodium, potassium, bicarbonate.

  7. Drug

    Coronavirus-Like Particle COVID-19 Vaccine

    go.drugbank.com/drugs/DB15852
    Experimental

    The vaccine was developed by creating SARS-Cov-2 virus-like particles (CoVLPs), which mimic the structure of the virus without carrying the genetic components required for infection. … In July 2020, Medicago partnered with Dynavax to test the vaccine with its adjuvant, Cpg 1018 (also known as [ISS-1018]), meant to provide an enhanced immune response to the vaccine.

  8. Drug

    Lipegfilgrastim

    go.drugbank.com/drugs/DB13200
    Approved

    The average molecular mass of lipegfilgrastim comprises 18,798 Da for [DB00099], 203 Da for GalNAc, 338 Da for glycylsialic acid and approximately 20,000 Da for PEG [L2449]. … It is used as an alternate to [DB00019] for prophylactic use in cancer patients receiving chemotherapy and at risk for developing chemotherapy-induced neutropenia.

  9. Drug

    Thiotepa

    go.drugbank.com/drugs/DB04572
    ApprovedInvestigational

    It is also used as conditioning for Bone marrow transplantation. Its main toxicity is myelosuppression. … N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years.

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  10. Drug

    L-Acetylleucine

    go.drugbank.com/drugs/DB16956
    ApprovedInvestigational

    [A264439] Observational studies in patients with Niemann-Pick disease type C (NPC) suggested a beneficial symptomatic as well as neuroprotective disease-modifying effect of the DL-form of N-acetylleucine … Levacetylleucine (L-acetylleucine) is a modified acetylated derivative of the amino acid [leucine]. The racemic (i.e. DL-) form has been available in France since 1957 for the treatment of vertigo.